The R&D³ Podcast

Our Research Scientist Jeet Roy is back again on our podcast to talk about Gastrointestinal disorders (GI) in the clinical trials space. Jeet takes a deeper dive into the ins and outs of GI when it comes to clinical trials, the different digital tools used for this TA in clinical trials, and a whole lot more!

In our second episode, we sat down with our Research Scientist Xinrui Jiang, PhD, to discuss a critical behavioral science component – motivation and rewards. In this episode, she’ll walk you through motivation and rewards, how they work from a behavioral science perspective, why they are essential in clinical trials, and how we’ve applied this particular component at Datacubed Health.

In this episode, we sat down with our Research Scientist, Elias Boroda, to discuss a crucial behavioral science component – identity lock. In this episode, Elias will talk about the concept of community and identity lock and how it can increase patient retention and compliance in clinical trials.

In our first podcast, we sat down with Chief Scientific Officer Marie Onakomaiya to discuss the principles of behavioral science, why it’s being leveraged in clinical trials, and how it can be used to drive instrument compliance and engagement among clinical trial participants.

In this episode, we meet with Susan Stein, a seasoned patient advocate, to discuss the pivotal role of patient advocacy in the realm of clinical trials. We focus on how advocacy influences the development of clinical trial protocols, with an emphasis on minimizing the challenges faced by patients, such as logistical and financial burdens. Key topics include the importance of incorporating patient input in trial planning, particularly in areas like informed consent and the frequency of site visits. Stein highlights the potential of technologies like telehealth to improve patient experiences while retaining critical in-person medical interactions. We also explore the increasing need for diversity in clinical trials and how patient advocacy is adapting to recent shifts in the clinical research industry.